Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Clevudine (L-FMAU; L FMAU; Levovir and Revovir) is a potent antiviral drug approved in South Korea and the Philippines for the treatment of hepatitis B (HBV) infections with EC50 0.1 μM in HepG2 2.2.15 cells as well as EBV. Numerous cell lines, such as MT2, CEM, H1, HepG2 2.2.15, and bone marrow progenitor cells, exhibit minimal cytotoxicity when exposed to clevodine exposure. In cells, clevudine is broken down into its monophosphate, then into its di- and triphosphates by cellular thymidine kinase and deoxycytidine kinase.
Targets |
RNA polymerase; DNA polymerase
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C10H13FN2O5
|
|
---|---|---|
Molecular Weight |
260.22
|
|
Exact Mass |
260.08
|
|
Elemental Analysis |
C, 46.16; H, 5.04; F, 7.30; N, 10.77; O, 30.74
|
|
CAS # |
163252-36-6
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F
|
|
InChi Key |
GBBJCSTXCAQSSJ-XQXXSGGOSA-N
|
|
InChi Code |
InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
|
|
Chemical Name |
1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.8429 mL | 19.2145 mL | 38.4290 mL | |
5 mM | 0.7686 mL | 3.8429 mL | 7.6858 mL | |
10 mM | 0.3843 mL | 1.9215 mL | 3.8429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04891302 | Completed | Drug: Clevudine Drug: Placebo |
COVID-19 | Bukwang Pharmaceutical | March 19, 2021 | Phase 2 |
NCT01192854 | Completed | Drug: Clevudine Drug: Adefovir |
Chronic Hepatitis B | Eisai Co., Ltd. | February 2010 | Phase 3 |
NCT00558818 | Completed | Drug: Clevudine | Chronic Hepatitis B | Bukwang Pharmaceutical | June 2007 | Phase 4 |
NCT04347915 | Completed | Drug: Clevudine Drug: Placebo |
COVID-19 | Bukwang Pharmaceutical | May 26, 2020 | Phase 2 |
NCT00558493 | Completed | Drug: Clevudine | Chronic Hepatitis B | Bukwang Pharmaceutical | November 2007 | Phase 4 |